Month: September 2026
LOS ANGELES–(BUSINESS WIRE)—- $HONA–HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit with SBS Law
東京–(BUSINESS WIRE)–(美國商業資訊)– NTT DOCOMO BUSINESS, Inc.（前身為NTT Communications Corporation）今日宣布推出docomo business SIGN®1產品線中的新服務「Pro」，這是一項針對物聯網的網路即服務(NaaS)，內建安全功能。「Pro」專為支援連網產品的大規模及全球化部署而設計，能夠協助客戶管理和營運數以萬計的物聯網連線。該服務將於2027年3月起正式推出。 這項新服務旨在解決以下挑戰：透過集中管理國內外物聯網連線、營運自動化以及系統整合來實現更先進的營運管理，同時強化安全性。它將減輕客戶的營運負擔，同時支援透過連網產品和服務持續創造價值。 1. 背景 近年來，在日本出生率下降和人口老齡化導致勞動力短缺的背景下，製造業、物流、醫療、社會基礎設施和行動運輸等各行各業都在尋求透過自動駕駛、遠端監控和AI應用實現節省人力的流程和更精細化的營運。為支援上述措施，內建通訊功能的車輛、工業機械、監控相機、醫療裝置等連網產品的採用正在不斷擴大。據GSMA Intelligence2預測，到2030年全
DALLAS–(BUSINESS WIRE)—- $LIB.v #criticalminerals–LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF | FSE: I2D) (“LibertyStream” or the “Company”) announces the appointment of Keirah Burrell, previously Vice President of Accounting Operations, as Interim Chief Financial Officer, succeeding Morgan Tiernan, who is retiring from the role. The transition comes as LibertyStream continues to develop its financial reporting, internal controls and systems in support of its previously announced plans for a li
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, are expected to be approximately $446.3 million. In addition, the underwriters have a 30-day option to purchase up to an additional 3,937,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
The shares are expected to begin trading on The Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.” The offering is expected to close on September 28, 2026, subject to the satisfaction of customary closing conditions.
J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering. LifeSci Capital is acting as a book-running manager for the offering.
Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 24, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010 or by email at ol-prospectus-request@ubs.com.
In addition, AbbVie has agreed to purchase, in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), a number of shares of ADARx’s common stock that would result in AbbVie owning approximately 4.9% of ADARx’s outstanding shares of common stock following the closing of the initial public offering and the concurrent private placement, at a price of $17.00 per share; provided, however, that in no event would AbbVie purchase more than $100.0 million in shares of common stock. The aggregate gross proceeds to ADARx from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering and private placement expenses payable by ADARx, are expected to be approximately $535.2 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. The concurrent private placement is also scheduled to close on September 28, 2026, subject to the satisfaction of customary closing conditions. The closing of the concurrent private placement is contingent and conditioned upon consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.
Forward-Looking Statements
The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believe,” “can,” “estimate,” “expect,” “intend,” “may,” “plans,” “should,” “seeks,” or “will,” or similar expressions which concern ADARx’s strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to ADARx’s expected gross proceeds from the initial public offering and concurrent private placement, the expected date for ADARx’s common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering and concurrent private placement. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. ADARx’s expectations, beliefs and projections are expressed in good faith and ADARx believes there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. ADARx undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
CONTACT: Contacts Investors: ir@adarx.com Media: teri@redhousecomms.com
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Tigo Energy, Inc. (NASDAQ: TYGO) between February 24, 2026 and August 4, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Tigo investors under the federal securities laws.To join the Tigo class action, go to https://rosenlegal.com/cases/tigo-energy-inc/join or call Phillip Kim, Esq. toll-free
CHICAGO–(BUSINESS WIRE)–ComEd today announced that customers participating in its Hourly Pricing program have saved more than $63 million on electricity supply costs to date while helping reduce energy demand during periods of peak electricity use. The program has reached a record 70,000 residential customers following its largest single year of growth since launching in 2007. More than 80 percent of participants reduced their electricity supply costs compared with ComEd’s standard fixed-pric
نيويورك–(BUSINESS WIRE)–أعلنت Elliptic، الشركة الرائدة عالميًا في مجال إدارة المخاطر على السلسلة، اليوم عن إطلاق Pulse. يضع Pulse أدوات تحديد أولويات الخيوط المرتبطة بالعملات المشفّرة مباشرةً في متناول كل مسؤول إنفاذ قانون وموظف حكومي في الخطوط الأمامية.باتت العملات المشفّرة اليوم جزءًا من مختلف جوانب عمل جهات إنفاذ القانون، بدءًا من ضابط الدورية في الشارع ووصولاً إلى المحقق المكلّف بالتحقيق في القضية. يمنح Pulse كلاً منهم ملخصًا ماليًا سريعًا ودقيقًا ونقطة انطلاق واضحة للتحقيق، سواء كان ذلك ع
費城–(BUSINESS WIRE)–(美國商業資訊)– 提供資料變現、資質認證和代幣化技術的人工智慧平台(AIP)公司Datavault AI Inc. (Nasdaq: DVLT)（簡稱「Datavault AI」或「公司」）今日宣布，其董事會（簡稱「董事會」）已核准向其普通股（簡稱「普通股」）及某些其他Datavault AI證券的持有人發行認股權。Moody Capital Solutions, Inc. (“Moody Capital”)將擔任本次認股權發行的承銷經理。 認股權發行將讓投資人參與通常僅限銀行參與的過程 根據認股權發行計畫，公司將免費向普通股及某些其他公司證券的登記持有人發行可轉讓認購權，這些持有人享有參與分配的合約權利。公司確定本次發行的登記日為2026年10月9日（簡稱「登記日」）。截至登記日，此類持有人每持有一股普通股將獲得一股普通股單位的認購權，每持有100股普通股將獲得一股優先股單位的認購權。 普通股單位 。每個普通股單位將包括：(i)一股普通股，(ii)一份購買一股普通股的A系列權利（簡稱「A系列權利」）以及(iii)一份購買一股普通股的B系列